ArticleFrontiers in endocrinology2025
The triglyceride-high-density lipoprotein-glucose-body index: a superior novel biomarker for diabetic kidney disease in type 2 diabetes.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Waist circumference partially mediates the non-linear association between TyHGB and MASLD in non-diabetic Japanese adults.Frontiers in nutrition · 2026Article
- TyG-HDL Outperforms TyG Combined With Obesity Indicators in Predicting Chronic Kidney Disease Associated With High Fasting Blood Glucose Levels in the Chinese Elderly Population: A Two-Stage Study Based on GBD 2023 and CHARLS Data.International journal of endocrinology · 2026Article
- The Triglyceride-Glucose-Chinese Visceral Adiposity Index (TyG-CVAI) outperforms other insulin resistance indices in its association with cardiovascular-kidney-metabolic syndrome severity in type 2 diabetes: a comparative study.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The triglyceride-glucose (TyG) index is a recognized surrogate marker of insulin resistance but lacks integration of high-density lipoprotein cholesterol (HDL-C) and adiposity measures, which are pivotal in the pathogenesis of diabetic kidney disease (DKD). The novel triglyceride-high-density lipoprotein-glucose-body (TyHGB) index, combining TG/HDL-C ratio, fasting blood glucose (FBG), and body mass index (BMI), may offer a more comprehensive metabolic profile. This study aimed to evaluate the associative value of TyHGB for DKD in type 2 diabetes mellitus (T2DM) patients. Methods: A retrospective cross-sectional analysis of 1,382 adults with T2DM was conducted. We employed multivariable logistic regression, restricted cubic spline (RCS) analysis, and subgroup analyses to assess the independent and non-linear association of the TyHGB index with DKD. Receiver operating characteristic (ROC) curves, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to evaluate and compare its associative performance against the TyG index. Results: Among the participants, 286 (20.7%) were diagnosed with DKD. After full adjustment for demographic, clinical, and biochemical confounders, TyHGB was independently associated with DKD (OR = 1.11, 95%CI:1.05-1.17, p<0.001). RCS analysis revealed a significant non-linear relationship, with a sharp increase in DKD risk beyond a TyHGB threshold of 8.74. The TyHGB index demonstrated superior discriminative ability (AUC = 0.775, 95% CI: 0.747-0.803) compared to the TyG index (AUC = 0.644, p<0.001). Incorporating TyHGB into a baseline clinical model significantly improved risk association (AUC increased from 0.715 to 0.788, p<0.001) and provided substantial reclassification improvement (NRI = 0.647, IDI = 0.067). Conclusion: The TyHGB index exhibits a robust, independent, and non-linear association with DKD risk in T2DM patients and outperforms the established TyG index. As a readily accessible composite metric, it holds significant promise as a superior tool for early identification and risk stratification of DKD in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.